Jipeng Wan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jipeng Wan has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Huaichao Liu
Department of Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China; Jinan Key Laboratory of Diagnosis and Treatment of Major Gynaecological Disease, Jinan, 250021, China
3 shared publications- Xiao Sun
Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China
2 shared publications Zihan Wang
Department of Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China; Jinan Key Laboratory of Diagnosis and Treatment of Major Gynaecological Disease, Jinan, 250021, China
2 shared publicationsAaron Kwan
California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA
1 shared publicationAnmin Wang
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA; California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA
1 shared publicationAudrey Qian
California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA
1 shared publication
Latest Publications
- Open Access
- 12 August 2025
- Published by Elsevier in EBioMedicine
- Vol. 119, 105884
Tumour extracellular vesicle surface Protein-mRNA integration assay for early detection of epithelial ovarian cancer
- 12 August 2025
- Published by Elsevier in EBioMedicine
- Vol. 119, 105884
Open AccessTumour extracellular vesicle surface Protein-mRNA integration assay for early detection of epithelial ovarian cancer
- Open Access
- 7 October 2024
- Published by Wiley in Advanced Science
- Vol. 11 (44) , e2409778
Injectable Magnetic Hydrogel Incorporated with Anti‐Inflammatory Peptide for Efficient Magnetothermal Treatment of Endometriosis
Endometriosis is a prevalent gynecological condition characterized by chronic pelvic pain, dysmenorrhea, and infertility, affecting ≈176 million women of reproductive age worldwide. Current treatments, including pharmacological and surgical interventions, are often associated with significant side effects and high recurrence rates. Consequently, there is an urgent need for innovative and safer therapeutic approaches. In this study, an injectable magnetic hydrogel nanosystem is developed designed for the dual‐purpose magnetothermal and anti‐inflammatory treatment of endometriosis. This hydrogel incorporates Fe3O4 nanoparticles alongside an anti‐inflammatory peptide. Upon magnetic activation, the Fe3O4 nanoparticles induce a localized hyperthermic response, raising the temperature of endometriotic lesions to 63.3 °C, effectively destroying endometriotic cells. Concurrently, the thermally responsive hydrogel facilitates the controlled release of the anti‐inflammatory peptide, thus modulating the inflammatory milieu. The biocompatibility and complete in vivo degradability of the hydrogel further enhance its therapeutic potential. The in vivo studies demonstrated that this injectable magnetic hydrogel system achieved a 90% reduction in the volume of endometriotic lesions and significantly decreased inflammatory markers, offering a promising non‐invasive treatment modality for endometriosis. By integrating precise lesion ablation with the modulation of the inflammatory microenvironment, this system represents a novel approach to the clinical management of endometriosis.
- 7 October 2024
- Published by Wiley in Advanced Science
- Vol. 11 (44) , e2409778
Open AccessInjectable Magnetic Hydrogel Incorporated with Anti‐Inflammatory Peptide for Efficient Magnetothermal Treatment of Endometriosis
Endometriosis is a prevalent gynecological condition characterized by chronic pelvic pain, dysmenorrhea, and infertility, affecting ≈176 million women of reproductive age worldwide. Current treatments, including pharmacological and surgical interventions, are often associated with significant side effects and high recurrence rates. Consequently, there is an urgent need for innovative and safer therapeutic approaches. In this study, an injectable magnetic hydrogel nanosystem is developed designed for the dual‐purpose magnetothermal and anti‐inflammatory treatment of endometriosis. This hydrogel incorporates Fe3O4 nanoparticles alongside an anti‐inflammatory peptide. Upon magnetic activation, the Fe3O4 nanoparticles induce a localized hyperthermic response, raising the temperature of endometriotic lesions to 63.3 °C, effectively destroying endometriotic cells. Concurrently, the thermally responsive hydrogel facilitates the controlled release of the anti‐inflammatory peptide, thus modulating the inflammatory milieu. The biocompatibility and complete in vivo degradability of the hydrogel further enhance its therapeutic potential. The in vivo studies demonstrated that this injectable magnetic hydrogel system achieved a 90% reduction in the volume of endometriotic lesions and significantly decreased inflammatory markers, offering a promising non‐invasive treatment modality for endometriosis. By integrating precise lesion ablation with the modulation of the inflammatory microenvironment, this system represents a novel approach to the clinical management of endometriosis.
- Open Access
- 24 May 2024
- Published by Elsevier in The Journal of Liquid Biopsy
- Vol. 5, 100158
Global research trends in liquid biopsy for ovarian cancer from 1999 to 2023: A 25-year bibliometric analysis
- 24 May 2024
- Published by Elsevier in The Journal of Liquid Biopsy
- Vol. 5, 100158
Open AccessGlobal research trends in liquid biopsy for ovarian cancer from 1999 to 2023: A 25-year bibliometric analysis
- 4 February 2022
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 213, 112393
A near-infrared triggered upconversion/MoS2 nanoplatform for tumour-targeted chemo-photodynamic combination therapy
- 4 February 2022
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 213, 112393
A near-infrared triggered upconversion/MoS2 nanoplatform for tumour-targeted chemo-photodynamic combination therapy